Mounjaro 12.5 mg Pfs

Tirzepatide belongs to a novel class of medications that act as a dual agonist, activating both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, hormones naturally involved in regulating blood sugar and appetite. By activating these receptors, Tirzepatide helps the body release insulin more effectively in response to meals, while also slowing stomach emptying and reducing appetite, which supports both blood sugar control and weight management. It is commonly used in adults with type 2 diabetes to help improve blood sugar control as part of a comprehensive treatment plan that includes diet and exercise. Tirzepatide is also used to support weight management in appropriate individuals, given its effect on appetite regulation and satiety. It is typically administered as a subcutaneous injection, given once weekly, offering a convenient dosing schedule for long-term management. Dosing usually starts at a lower level and is gradually increased over time, as directed by a healthcare provider, to help the body adjust and support optimal effectiveness. Many patients experience meaningful improvements in blood sugar control and body weight with consistent, long-term use. Regular follow-up with a healthcare provider helps monitor progress and adjust treatment as needed. As with all injectable medications, Tirzepatide should be used under the guidance of a healthcare provider as part of a personalized care plan.